LAUSR

The patient was a 65-year-old man (a nonsmoker) with a past history of nasal polyps and late-onset bronchial asthma that was very difficult to control. He had been hospitalized multiple times and was a long-term user of oral prednisone at a dosage of 15 mg daily. In April 2015, the patient was enrolled by the pulmonology department in a clinical trial that compared lebrikizumab to placebo; the first step was to gradually reduce his prednisone dosage to 2.5 mg daily. A week after this dosage was reached, the patient had an asthma exacerbation and very pruritic lesions appeared on the scalp, accompanied 15 days later by paresthesia, pain, and complete hemiplegia of the lower right limb.